Navamedic launches innovative parkinson’s treatment device in Europe

Navamedic ASA announced the launch of Flexilev® in OraFID®, a new single-use dosing dispenser for Parkinson's treatment, available for prescription at pharmacies by late December/early January. This novel drug-device combination aims to fine-tune levodopa treatment for patients experiencing variations in motor abilities, minimizing under- or overdosing and associated side effects. Chief executive Kathrine Gamborg Andreassen highlighted the commitment to improving patient outcomes through personalized treatment solutions using minitablets.

Navamedic ASA will manage the launch and marketing in Sweden, Norway, and Denmark. Separately, Orion Corporation has secured exclusive rights to market, distribute, and sell the product across 27 European countries, serving as the marketing authorization holder in those territories.